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alone. (Funded by Bristol-Myers Squibb; CheckMate 067 ClinicalTrials.gov number, NCT01844505.).
DOI: 10.1056/NEJMoa1504030
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-113016
Published Version
Originally published at:
Larkin, James; Chiarion-Sileni, Vanna; Gonzalez, Rene; Grob, Jean Jacques; Cowey, C Lance; Lao,
Christopher D; Schadendorf, Dirk; Dummer, Reinhard; Smylie, Michael; Rutkowski, Piotr; Ferrucci,
Pier F; Hill, Andrew; Wagstaff, John; Carlino, Matteo S; Haanen, John B; Maio, Michele; Marquez-
Rodas, Ivan; McArthur, Grant A; Ascierto, Paolo A; Long, Georgina V; Callahan, Margaret K; Postow,
Michael A; Grossmann, Kenneth; Sznol, Mario; Dreno, Brigitte; Bastholt, Lars; Yang, Arvin; Rollin,
Linda M; Horak, Christine; Hodi, F Stephen; Wolchok, Jedd D (2015). Combined Nivolumab and
Ipilimumab or monotherapy in untreated melanoma. New England Journal of Medicine, 373(1):23-34.
DOI: 10.1056/NEJMoa1504030
2
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med nejm.org 1
The authors’ full names, academic de‑
grees, and affiliations are listed in the Ap‑
pendix. Address reprint requests to Dr. 
Hodi at Dana–Farber Cancer Institute, 
450 Brookline Ave., Boston, MA 02215, or 
at  stephen_hodi@ dfci . harvard . edu; or to 
Dr. Wolchok at the Department of Medi‑
cine and Ludwig Center, Memorial Sloan 
Kettering Cancer Center, 1275 York Ave., 
Box 340, New York, NY 10065, or at 
 wolchokj@ mskcc . org.
Drs. Hodi and Wolchok contributed equal‑
ly to this article.
This article was published on May 31, 2015, 
at NEJM.org.
DOI: 10.1056/NEJMoa1504030
Copyright © 2015 Massachusetts Medical Society.
BACKGROUND
Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab 
(a cytotoxic T-lymphocyte–associated antigen 4 [CTLA-4] checkpoint inhibitor) have 
been shown to have complementary activity in metastatic melanoma. In this ran-
domized, double-blind, phase 3 study, nivolumab alone or nivolumab plus ipilim-
umab was compared with ipilimumab alone in patients with metastatic melanoma.
METHODS
We assigned, in a 1:1:1 ratio, 945 previously untreated patients with unresectable 
stage III or IV melanoma to nivolumab alone, nivolumab plus ipilimumab, or ipilim-
umab alone. Progression-free survival and overall survival were coprimary end points. 
Results regarding progression-free survival are presented here.
RESULTS
The median progression-free survival was 11.5 months (95% confidence interval [CI], 
8.9 to 16.7) with nivolumab plus ipilimumab, as compared with 2.9 months (95% CI, 
2.8 to 3.4) with ipilimumab (hazard ratio for death or disease progression, 0.42; 
99.5% CI, 0.31 to 0.57; P<0.001), and 6.9 months (95% CI, 4.3 to 9.5) with nivolum-
ab (hazard ratio for the comparison with ipilimumab, 0.57; 99.5% CI, 0.43 to 0.76; 
P<0.001). In patients with tumors positive for the PD-1 ligand (PD-L1), the median 
progression-free survival was 14.0 months in the nivolumab-plus-ipilimumab 
group and in the nivolumab group, but in patients with PD-L1–negative tumors, 
progression-free survival was longer with the combination therapy than with 
nivolumab alone (11.2 months [95% CI, 8.0 to not reached] vs. 5.3 months [95% CI, 
2.8 to 7.1]). Treatment-related adverse events of grade 3 or 4 occurred in 16.3% of 
the patients in the nivolumab group, 55.0% of those in the nivolumab-plus-ipilim-
umab group, and 27.3% of those in the ipilimumab group.
CONCLUSIONS
Among previously untreated patients with metastatic melanoma, nivolumab alone 
or combined with ipilimumab resulted in significantly longer progression-free sur-
vival than ipilimumab alone. In patients with PD-L1–negative tumors, the combination 
of PD-1 and CTLA-4 blockade was more effective than either agent alone. (Funded 
by Bristol-Myers Squibb; CheckMate 067 ClinicalTrials.gov number, NCT01844505.)
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Considerable progress in the treat-ment of metastatic melanoma has been made in the past 5 years, with the approval 
of immune checkpoint–blocking antibodies and, 
in parallel, agents targeting aberrant signaling in 
the 40 to 50% of melanomas with BRAF muta-
tions.1-6 Ipilimumab, an anti–cytotoxic T-lympho-
cyte–associated antigen 4 (CTLA-4) antibody, acts 
to up-regulate antitumor immunity and was the 
first agent to be associated with an improvement 
in overall survival in a phase 3 study involving pa-
tients with metastatic melanoma.5,6 Ipilimumab 
was associated with responses in 10% and 15% 
of patients5,6; approximately 20% of treated pa-
tients had long-term survival.7,8
Two anti–programmed death 1 (PD-1) anti-
bodies, nivolumab and pembrolizumab, were ap-
proved by the Food and Drug Administration in 
2014 for the treatment of metastatic melanoma 
after progression during ipilimumab treatment 
and, in patients with BRAF-mutated melanoma, 
after progression during treatment with a BRAF 
inhibitor. These antibodies were associated with 
objective responses in 30 to 40% of patients, with 
the majority of responses being durable. Two 
phase 3 trials have shown superior efficacy of 
nivolumab, as compared with chemotherapy, in 
previously untreated patients with wild-type BRAF 
tumors9 or in patients with either mutant or wild-
type BRAF tumors after progression during ipili-
mumab therapy and, in patients with tumors posi-
tive for BRAF mutation, after progression during 
treatment with a BRAF inhibitor.10 Similar results 
were observed in a phase 2 trial of pembrolizumab 
versus chemotherapy.11 Recently, pembrolizumab 
was associated with longer progression-free sur-
vival and overall survival and higher response 
rates than those associated with ipilimumab in 
a phase 3 trial involving patients with advanced 
melanoma.12
The results of a phase 2 study that compared 
combined nivolumab and ipilimumab with ipili-
mumab alone in patients with BRAF wild-type 
melanoma showed objective response rates of 61% 
with the combination therapy and 11% with the 
monotherapy, with complete responses in 22% and 
0% of patients, respectively.13 Treatment-related 
adverse events of grade 3 or 4 were reported in 
54% of the patients in the combination group and 
in 24% of those in the ipilimumab group. Expres-
sion of the PD-1 ligand, PD-L1, has been reported 
to result in greater benefit with anti–PD-1 mono-
therapy9,10 but not with the combination of anti–
PD-1 and anti–CTLA-4 therapy.13,14 However, effec-
tive cutoff points for defining PD-L1 expression 
and clinical usefulness have not yet been estab-
lished.
To confirm and extend these findings, we re-
port one of the coprimary end points (progression-
free survival) of a randomized, double-blind, mul-
ticenter, phase 3 trial (CheckMate 067) that was 
conducted to evaluate the safety and efficacy of 
nivolumab alone or nivolumab combined with 
ipilimumab in comparison with ipilimumab 
alone in patients with previously untreated met-
astatic melanoma. Data on overall survival are 
insufficiently mature to present.
Me thods
Patients
Eligible patients had histologically confirmed 
stage III (unresectable) or stage IV melanoma and 
had received no prior systemic treatment for ad-
vanced disease. Other eligibility criteria included 
an age of at least 18 years; an Eastern Cooperative 
Oncology Group (ECOG) performance-status score 
of 0, indicating no symptoms, or 1, indicating 
mild symptoms (on a scale from 0 to 5, with 
higher scores indicating greater disability); mea-
surable disease as assessed by means of com-
puted tomography or magnetic resonance imag-
ing according to Response Evaluation Criteria in 
Solid Tumors (RECIST), version 1.115; availability 
of tissue collected from metastatic or unresect-
able tumors (archival or recently biopsied samples) 
for the assessment of PD-L1 status; and known 
BRAF V600 mutation status. Key exclusion criteria 
were an ECOG performance-status score of 2 (in-
dicating moderate symptoms, with the patient 
being ambulatory and capable of all self-care but 
unable to carry out any work activities) or higher 
and the presence of active brain metastases, oc-
ular melanoma, or autoimmune disease.
Study Design and Treatment
In this double-blind, phase 3 study, enrolled pa-
tients were randomly assigned in a 1:1:1 ratio 
to receive one of the following regimens: 3 mg 
of nivolumab per kilogram of body weight every 
2 weeks (plus ipilimumab-matched placebo); 1 mg 
of nivolumab per kilogram every 3 weeks plus 3 mg 
of ipilimumab per kilogram every 3 weeks for 
4 doses, followed by 3 mg of nivolumab per ki-
The New England Journal of Medicine 
Downloaded from nejm.org at HAUPTBIBLIOTHEK UNIV ZUERICH on May 31, 2015. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
n engl j med nejm.org 3
Nivolumab and Ipilimumab in Untreated Melanoma
logram every 2 weeks for cycle 3 and beyond; or 
3 mg of ipilimumab per kilogram every 3 weeks 
for 4 doses (plus nivolumab-matched placebo). 
Both nivolumab and ipilimumab were adminis-
tered by means of intravenous infusion.
Randomization was stratified according to 
tumor PD-L1 status (positive vs. negative or in-
determinate), BRAF mutation status (V600 muta-
tion–positive vs. wild-type), and American Joint 
Committee on Cancer metastasis stage (M0, M1a, 
or M1b vs. M1c). Treatment continued until dis-
ease progression (as defined by RECIST, version 
1.1), development of unacceptable toxic events, 
or withdrawal of consent. Patients could be treated 
after progression, provided that they had a clini-
cal benefit and did not have substantial adverse 
effects, as assessed by the investigator (further 
details are provided in the study protocol, available 
with the full text of this article at NEJM.org).
Progression-free survival and overall survival 
were coprimary end points; results regarding pro-
gression-free survival are presented here. Second-
ary and other end points included objective re-
sponse rate, tumor PD-L1 expression as a predictive 
biomarker for efficacy outcomes, and safety.
Assessments
Patients were assessed for tumor response, ac-
cording to RECIST, version 1.1,15 at 12 weeks after 
randomization, then every 6 weeks for 49 weeks, 
and then every 12 weeks until progression or treat-
ment discontinuation, whichever occurred later. 
Progression-free survival was defined as the 
time between the date of randomization and the 
date of documented progression or death, which-
ever occurred first. Patients treated after pro-
gression were considered to have had progres-
sive disease at the time of the initial progression 
event, as assessed by the investigator, regardless 
of subsequent tumor responses.
Expression of PD-L1 on the surface of the 
tumor cells was assessed in a central laboratory 
by means of immunohistochemical testing in for-
malin-fixed, paraffin-embedded tumor specimens 
with the use of a rabbit monoclonal antihuman 
PD-L1 antibody (clone 28–8) and an analytically 
validated automated assay developed by Dako. 
PD-L1 positivity was defined as at least 5% of 
tumor cells showing PD-L1 staining of any inten-
sity on the cell surface in a section containing at 
least 100 tumor cells that could be evaluated.
Any patient who received at least one dose of 
study drug was included in the assessment of 
safety. The severity of adverse events was graded 
according to the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events, 
version 4.0.16 Safety assessments were made con-
tinuously during the treatment phase and up to 
100 days after the last dose of study drug. Guide-
lines for the management of adverse events were 
provided by the sponsor and have been published 
previously.9,10,13
Study Oversight
The study protocol and all amendments were ap-
proved by the institutional review board at each 
participating study site and are available (along 
with the statistical analysis plan) at NEJM.org. 
The study was conducted in accordance with the 
provisions of the Declaration of Helsinki and with 
Good Clinical Practice guidelines as defined by 
the International Conference on Harmonisation. 
All the patients (or their legal representatives) pro-
vided written informed consent before enrollment. 
The trial was designed as a collaboration between 
the senior academic authors and the sponsor, 
Bristol-Myers Squibb. Data were collected by the 
sponsor and analyzed in collaboration with all 
the authors.
All the authors vouch for the accuracy and 
completeness of the data and analyses reported 
and for the fidelity of the study to the protocol. 
The first draft of the manuscript was prepared 
by the first and last authors. All the authors con-
tributed to subsequent drafts and provided final 
approval to submit the manuscript for publication. 
Medical-writing support, funded by the sponsor, 
was provided by StemScientific.
A data and safety monitoring committee was 
established to provide oversight of safety and ef-
ficacy considerations, in order to assess the ben-
efit–risk profile of nivolumab combined with 
ipilimumab. As per the statistical analysis plan, 
the results of the coprimary end point of pro-
gression-free-survival were released by the mon-
itoring committee on March 17, 2015, after a posi-
tive statistical outcome. The study remains blinded 
with respect to overall survival because follow-
up of the patients is planned to continue until 
the specified number of events have occurred.
Statistical Analysis
A study sample of approximately 915 patients was 
planned. For the comparison of progression-free 
The New England Journal of Medicine 
Downloaded from nejm.org at HAUPTBIBLIOTHEK UNIV ZUERICH on May 31, 2015. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
n engl j med nejm.org 4
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
survival, we estimated that the number of events 
that was projected to be observed at a follow-up 
of at least 9 months would give the study approxi-
mately 83% power to detect an average hazard 
ratio of 0.71 at a type I error rate of 0.005 (two-
sided) for all comparisons. Progression-free sur-
vival was compared between the nivolumab group 
or the nivolumab-plus-ipilimumab group and the 
ipilimumab group, with the use of a two-sided log-
rank test with stratification as described above. 
The study was not designed for a formal statisti-
cal comparison between the nivolumab group and 
the nivolumab-plus-ipilimumab group.
Hazard ratios and corresponding two-sided 
99.5% confidence intervals were estimated with 
the use of a Cox proportional-hazards model, with 
treatment group as a single covariate, stratified 
according to the factors listed above. Progression-
free survival curves, medians with 95% confidence 
intervals, and progression-free survival rates at 6, 
12, and 18 months with 95% confidence inter-
vals were estimated with the use of the Kaplan–
Meier method.
R esult s
Patients and Treatment
From July 2013 through March 2014, a total of 
1296 patients were enrolled at 137 centers in Aus-
tralia, Europe, Israel, New Zealand, and North 
America. A total of 945 patients underwent ran-
domization: 316 patients were assigned to the 
nivolumab group, 314 to the nivolumab-plus-
ipilimumab group, and 315 to the ipilimumab 
group (Fig. S1 in the Supplementary Appendix, 
available at NEJM.org). Baseline characteristics 
were balanced across the three groups. A total 
of 58.0% of the patients had stage M1c disease, 
36.1% had an elevated lactate dehydrogenase lev-
el, 31.5% had a BRAF mutation, and 23.6% had 
positive PD-L1 status (Table 1).
The database lock occurred on February 17, 
2015. At a median follow-up ranging from 12.2 
to 12.5 months across the three groups, 117 of 
313 patients (37.4%) in the nivolumab group, 93 
of 313 (29.7%) in the nivolumab-plus-ipilimumab 
group, and 50 of 311 (16.1%) in the ipilimumab 
group were continuing study treatment (Table S1 
in the Supplementary Appendix). The most fre-
quent reason for discontinuation was disease 
progression in the nivolumab and ipilimumab 
monotherapy groups (154 of 313 patients [49.2%] 
and 202 of 311 [65.0%], respectively) and toxic 
effects of the study drug in the nivolumab-plus-
ipilimumab group (120 of 313 [38.3%]).
The median number of doses was 15 (range, 
1 to 38) in the patients who received nivolumab 
alone and 4 (range, 1 to 4) in those who received 
ipilimumab alone. In the nivolumab-plus-ipilim-
umab group, the median number of doses was 4 
(range, 1 to 39) of nivolumab and 4 (range, 1 to 4) 
of ipilimumab; 147 of 313 patients (47.0%) received 
more than 4 doses of nivolumab monotherapy.
Efficacy
The median progression-free survival was 6.9 
months (95% confidence interval [CI], 4.3 to 9.5) 
in the nivolumab group, 11.5 months (95% CI, 
8.9 to 16.7) in the nivolumab-plus-ipilimumab 
group, and 2.9 months (95% CI, 2.8 to 3.4) in the 
ipilimumab group. Significantly longer progres-
sion-free survival was observed in the nivolumab-
plus-ipilimumab group than in the ipilimumab 
group (hazard ratio for death or disease progres-
sion, 0.42; 99.5% CI, 0.31 to 0.57; P<0.001) and 
in the nivolumab group than in the ipilimumab 
group (hazard ratio, 0.57; 99.5% CI, 0.43 to 0.76; 
P<0.001) (Fig. 1A). The hazard ratio for the com-
parison between the nivolumab-plus-ipilimumab 
group and the nivolumab group was 0.74 (95% CI, 
0.60 to 0.92).
Analyses of progression-free survival in pre-
specified subgroups showed consistently longer 
progression-free survival with nivolumab or with 
nivolumab plus ipilimumab than with ipilimu-
mab, including in subgroups defined according 
to PD-L1 status, BRAF mutation status, and metas-
tasis stage (Fig. 1B and 1C, and Fig. S2 in the 
Supplementary Appendix). In the nivolumab-plus-
ipilimumab group, the median progression-free 
survival was 11.7 months (95% CI, 8.0 to not 
reached) among patients with a BRAF mutation 
and 11.2 months (95% CI, 8.3 to not reached) 
among patients with wild-type BRAF.
Among patients with a positive PD-L1 tumor 
status, the median progression-free survival was 
14.0 months (95% CI, 9.1 to not reached) in the 
nivolumab group, 14.0 months (95% CI, 9.7 to 
not reached) in the nivolumab-plus-ipilimumab 
group, and 3.9 months (95% CI, 2.8 to 4.2) in 
the ipilimumab group (Fig. 1B). Among patients 
with a negative PD-L1 tumor status, the median 
progression-free survival was 5.3 months (95% 
CI, 2.8 to 7.1), 11.2 months (95% CI, 8.0 to not 
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Characteristic
Nivolumab 
(N = 316)
Nivolumab plus 
Ipilimumab 
(N = 314)
Ipilimumab 
(N = 315)
Total 
(N = 945)
Age — yr
Mean 59 59 61 60
Range 25–90 18–88 18–89 18–90
Age category — no. (%)
<65 yr 198 (62.7) 185 (58.9) 182 (57.8) 565 (59.8)
≥65 to <75 yr 79 (25.0) 94 (29.9) 89 (28.3) 262 (27.7)
≥75 yr 39 (12.3) 35 (11.1) 44 (14.0) 118 (12.5)
Sex — no. (%)
Male 202 (63.9) 206 (65.6) 202 (64.1) 610 (64.6)
Female 114 (36.1) 108 (34.4) 113 (35.9) 335 (35.4)
ECOG performance‑status score — 
no. (%)†
0 238 (75.3) 230 (73.2) 224 (71.1) 692 (73.2)
1 77 (24.4) 83 (26.4) 91 (28.9) 251 (26.6)
2 1 (0.3) 0 0 1 (0.1)
Not reported 0 1 (0.3) 0 1 (0.1)
Metastasis stage — no. (%)
M1c 184 (58.2) 181 (57.6) 183 (58.1) 548 (58.0)
M0, M1a, or M1b 132 (41.8) 133 (42.4) 132 (41.9) 397 (42.0)
Lactate dehydrogenase — no. (%)
≤ULN 196 (62.0) 199 (63.4) 194 (61.6) 589 (62.3)
>ULN 112 (35.4) 114 (36.3) 115 (36.5) 341 (36.1)
≤2× ULN 271 (85.8) 276 (87.9) 279 (88.6) 826 (87.4)
>2× ULN 37 (11.7) 37 (11.8) 30 (9.5) 104 (11.0)
Unknown 8 (2.5) 1 (0.3) 6 (1.9) 15 (1.6)
Brain metastases — no. (%)
Yes 8 (2.5) 11 (3.5) 15 (4.8) 34 (3.6)
No 308 (97.5) 303 (96.5) 300 (95.2) 911 (96.4)
PD‑L1 status — no. (%)
Positive 80 (25.3) 68 (21.7) 75 (23.8) 223 (23.6)
Negative 208 (65.8) 210 (66.9) 202 (64.1) 620 (65.6)
Could not be determined or 
evaluated
28 (8.9) 36 (11.5) 38 (12.1) 102 (10.8)
BRAF status — no. (%)
Mutation 100 (31.6) 101 (32.2) 97 (30.8) 298 (31.5)
No mutation 216 (68.4) 213 (67.8) 218 (69.2) 647 (68.5)
*  There were no significant between‑group differences at baseline. PD‑L1 denotes programmed death 1 ligand, and ULN 
upper limit of the normal range.
†  Eastern Cooperative Oncology Group (ECOG) performance‑status scores range from 0 to 5, with higher scores indicat‑
ing greater disability. A score of 0 indicates no symptoms, 1 mild symptoms, and 2 moderate symptoms, with the pa‑
tient being ambulatory and capable of all self‑care but unable to carry out any work activities. Two patients were inad‑
vertently enrolled in the study: one patient with an ECOG performance‑status score of 2 was randomly assigned to the 
nivolumab group, and one whose ECOG performance‑status score was not reported was randomly assigned to the 
nivolumab‑plus‑ipilimumab group.
Table 1. Characteristics of the Patients at Baseline.*
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B Patients with PD-L1–Positive Tumors
A Intention-to-Treat Population
C Patients with PD-L1–Negative Tumors
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reached), and 2.8 months (95% CI, 2.8 to 3.1), re-
spectively (Fig. 1C).
The rates of investigator-assessed objective 
response were 43.7% (95% CI, 38.1 to 49.3) in the 
nivolumab group, 57.6% (95% CI, 52.0 to 63.2) in 
the nivolumab-plus-ipilimumab group, and 19.0% 
(95% CI, 14.9 to 23.8) in the ipilimumab group 
(Table 2). The percentage of patients with a com-
plete response was higher in the nivolumab-plus-
ipilimumab group (11.5%) than in either the 
nivolumab group (8.9%) or the ipilimumab group 
(2.2%) (Table 2). The time to an objective response 
was similar in the three groups (Table 2), and 
the median duration of response was not reached 
in any group.
The tumor-burden change was assessed as the 
change from baseline in the sum of the longest 
diameters of the target tumor lesions. The median 
change was −34.5% (interquartile range, −75.4 
to 15.4) in the nivolumab group, −51.9% (inter-
quartile range, −75.8 to −10.2) in the nivolumab-
plus-ipilimumab group, and 5.9% (interquartile 
range, −28.0 to 33.3) in the ipilimumab group 
(Fig. 2).
Among patients with PD-L1–positive tumors, 
the objective response rates were 57.5% (95% CI, 
45.9 to 68.5) in the nivolumab group, 72.1% (95% 
CI, 59.9 to 82.3) in the nivolumab-plus-ipilimu-
mab group, and 21.3% (95% CI, 12.7 to 32.3) in the 
ipilimumab group. Among patients with PD-L1–
negative tumors, the objective response rates were 
41.3% (95% CI, 34.6 to 48.4), 54.8% (95% CI, 
47.8 to 61.6), and 17.8% (95% CI, 12.8 to 23.8), 
Variable
Nivolumab 
(N = 316)
Nivolumab plus 
Ipilimumab 
(N = 314)
Ipilimumab 
(N = 315)
Best overall response — no. (%)*
Complete response 28 (8.9) 36 (11.5) 7 (2.2)
Partial response 110 (34.8) 145 (46.2) 53 (16.8)
Stable disease 34 (10.8) 41 (13.1) 69 (21.9)
Progressive disease 119 (37.7) 71 (22.6) 154 (48.9)
Could not be determined 25 (7.9) 21 (6.7) 32 (10.2)
Objective response†
No. of patients with response 138 181 60
% of patients (95% CI) 43.7 (38.1–49.3) 57.6 (52.0–63.2) 19.0 (14.9–23.8)
Estimated odds ratio (95% CI)‡ 3.40 (2.02–5.72) 6.11 (3.59–10.38) —
Two‑sided P value <0.001 <0.001 —
Time to objective response — mo
Median 2.78 2.76 2.79
Range 2.3–12.5 1.1–11.6 2.5–12.4
*  The best overall response was assessed by the investigator according to the Response Evaluation Criteria in Solid 
Tumors, version 1.1.
†  Data included patients with a complete response and those with a partial response. The calculation of the confidence 
interval was based on the Clopper–Pearson method. These analyses were conducted with the use of a two‑sided 
Cochran–Mantel–Haenszel test stratified according to PD‑L1 status, BRAF mutation status, and metastasis stage.
‡  The comparison is with the ipilimumab group.
Table 2. Response to Treatment.
Figure 1 (facing page). Progression-free Survival.
Panel A shows the Kaplan–Meier curves for progres‑
sion‑free survival in the intention‑to‑treat population. 
Patients were followed for a minimum of 9 months. 
The median progression‑free survival was 6.9 months 
(95% CI, 4.3 to 9.5) in the nivolumab group, 11.5 
months (95% CI, 8.9 to 16.7) in the nivolumab‑plus‑
ipilimumab group, and 2.9 months (95% CI, 2.8 to 
3.4) in the ipilimumab group. Significantly longer pro‑
gression‑free survival was observed in the nivolumab‑
plus‑ipilimumab group than in the ipilimumab group 
(hazard ratio for death or disease progression, 0.42; 
99.5% CI, 0.31 to 0.57; P<0.001) and in the nivolumab 
group than in the ipilimumab group (hazard ratio, 
0.57; 99.5% CI, 0.43 to 0.76; P<0.001). Panels B and C 
show the Kaplan–Meier curves for progression‑free 
survival among patients with tumors that were posi‑
tive for the programmed death 1 ligand (PD‑L1) and 
among those with PD‑L1–negative tumors, respectively.
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respectively (Table S2 in the Supplementary Ap-
pendix).
Adverse Events
Treatment-related adverse events of any grade 
occurred in 82.1% of the patients in the nivolu-
mab group, 95.5% of those in the nivolumab-
plus-ipilimumab group, and 86.2% of those in the 
ipilimumab group (Table 3). The most common 
adverse events in the nivolumab-plus-ipilimu-
mab group were diarrhea (in 44.1% of patients), 
fatigue (in 35.1%), and pruritus (in 33.2%). The 
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incidence of treatment-related adverse events of 
grade 3 or 4 was also higher in the nivolumab-
plus-ipilimumab group (55.0%) than in the 
nivolumab group (16.3%) or the ipilimumab 
group (27.3%).
Treatment-related adverse events of any grade 
that led to discontinuation of the study drug oc-
curred in 7.7% of the patients in the nivolumab 
group, 36.4% of those in the nivolumab-plus-
ipilimumab group, and 14.8% of those in the 
ipilimumab group, with the most common events 
being diarrhea (in 1.9%, 8.3%, and 4.5%, respec-
tively) and colitis (in 0.6%, 8.3%, and 7.7%, re-
spectively). One death due to toxic effects of the 
study drug was reported in the nivolumab group 
(neutropenia) and one in the ipilimumab group 
(cardiac arrest), but none were reported in the 
nivolumab-plus-ipilimumab group.
Select adverse events — defined as those with 
a potential immunologic cause — were analyzed 
according to organ category, as in previous stud-
ies.9,10 The most frequent treatment-related select 
adverse events of grade 3 or 4 were diarrhea (in 
2.2% of patients in the nivolumab group, 9.3% 
of those in the nivolumab-plus-ipilimumab group, 
and 6.1% of those in the ipilimumab group), coli-
tis (in 0.6%, 7.7%, and 8.7%, respectively), and in-
creased alanine aminotransferase level (in 1.3%, 
8.3%, and 1.6%, respectively) (Table S3 in the 
Supplementary Appendix).
Immune modulatory agents, including topical 
agents, to manage adverse events were used in 
47.0% of the patients in the nivolumab group, 
83.4% of those in the nivolumab-plus-ipilimumab 
group, and 55.9% of those in the ipilimumab 
group, with secondary immunosuppressive agents 
(e.g., infliximab) used in 0.6%, 6.1%, and 5.1% 
of the patients, respectively. Resolution rates for 
select adverse events of grade 3 or 4 were between 
85 and 100% in the nivolumab-plus-ipilimumab 
group for most organ categories (Table S4 in the 
Supplementary Appendix). As in prior studies, 
most endocrine events did not resolve.
Discussion
In this randomized, double-blind, phase 3 study 
involving patients with previously untreated ad-
vanced melanoma, treatment with nivolumab 
alone or with the combination of nivolumab and 
ipilimumab resulted in significantly longer pro-
gression-free survival and higher objective re-
sponse rates than did treatment with ipilimumab 
alone. In the two nivolumab-containing groups, 
as compared with ipilimumab, these results were 
observed independently of PD-L1 tumor status, 
BRAF mutation status, or metastasis stage. The 
characteristics of the study participants at base-
line were typical of patients with advanced mela-
noma, although the proportion of patients with 
BRAF mutation (31.5%) was lower than the 40 to 
50% that is generally reported for patients with 
advanced disease.17 Although the study was not 
designed for a formal statistical comparison be-
tween the nivolumab group and the nivolumab-
plus-ipilimumab group, the combination of 
nivolumab and ipilimumab resulted in numerically 
longer progression-free survival and a higher 
rate of response than did nivolumab alone in the 
overall study population.
The median progression-free survival that 
was observed with the combination of nivolu-
mab and ipilimumab in this study (11.7 months in 
patients with BRAF mutation) is similar to that 
recently reported with combined BRAF and MEK 
inhibition in patients with BRAF-mutated meta-
static melanoma (9.9 months with vemurafenib 
and cobimetinib2 and 9.3 to 11.4 months with 
dabrafenib and trametinib3,4). However, it remains 
unclear how the duration of response with 
nivolumab and ipilimumab compares with that 
observed with combined BRAF and MEK inhibi-
tion. The rate of objective response in the nivolu-
Figure 2 (facing page). Tumor-Burden Change  
in Target Lesions.
The waterfall plots show the maximum change from 
baseline in the sum of the reference diameters of the 
target lesion in patients receiving nivolumab (Panel 
A), nivolumab plus ipilimumab (Panel B), or ipilimum‑
ab (Panel C). Data are shown for all the patients who 
had target lesions evaluated at baseline and who un‑
derwent at least one tumor assessment during treat‑
ment. The percentage increase was truncated at 100% 
(rectangles). Asterisks indicate patients who had a re‑
sponse to treatment according to the Response Evalu‑
ation Criteria in Solid Tumors (RECIST), version 1.1. 
The horizontal dashed lines indicate a 30% reduction 
in the tumor burden in the target lesion, and the verti‑
cal dashed lines indicate the inflection point for the 
nivolumab‑plus‑ipilimumab group. The change in tu‑
mor burden was defined as the percentage decrease 
in the sum of the reference diameters of the target le‑
sion from baseline to nadir, observed up until the date 
of progression, as assessed by the investigator per RE‑
CIST, version 1.1, the date of subsequent anticancer 
therapy (including tumor‑directed radiotherapy and 
tumor‑directed surgery), or death, whichever occurred 
first.
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mab-plus-ipilimumab group (57.6%) is numerical-
ly higher than that observed with PD-1 blockade 
alone in patients with advanced melanoma (40% 
with nivolumab in previously untreated patients 
with wild-type BRAF9 or 33% with pembrolizumab 
in previously treated patients and previously un-
treated patients12). Given the results of a phase 1 
trial in which nivolumab plus ipilimumab was 
associated with a survival rate of 79% at 2 years,18 
as well as the long-term survival data reported 
for ipilimumab,7,8 it will be interesting to deter-
mine whether the efficacy results reported here 
will be reflected in an overall survival benefit.
The results of subgroup analyses suggest that 
the greatest benefit with the combination of 
nivolumab and ipilimumab versus nivolumab 
alone may occur in the context of negative PD-L1 
tumor expression. In the subgroup of patients 
with PD-L1–positive tumors, both nivolumab 
alone and nivolumab plus ipilimumab resulted in 
a similar prolongation of progression-free survival 
as compared with ipilimumab alone, although 
objective response rates were numerically higher 
in the combination group than in either mono-
therapy group. Thus, the use of PD-L1 as a bio-
marker may allow clinicians to make more in-
formed decisions about the benefit–risk ratio of 
combination therapy versus monotherapy. How-
ever, caution is warranted in interpreting these 
data because the effects on overall survival are 
not yet known and because the most effective 
method and cutoff point for assaying PD-L1 ex-
pression remain to be determined. Nonetheless, 
the observation of at least additive activity of the 
Event
Nivolumab 
(N = 313)
Nivolumab plus Ipilimumab 
(N = 313)
Ipilimumab 
(N = 311)
Any Grade 3 or 4 Any Grade 3 or 4 Any Grade 3 or 4
number of patients with event (percent)
Any adverse event 311 (99.4) 136 (43.5) 312 (99.7) 215 (68.7) 308 (99.0) 173 (55.6)
Treatment‑related adverse event† 257 (82.1) 51 (16.3) 299 (95.5) 172 (55.0) 268 (86.2) 85 (27.3)
Diarrhea 60 (19.2) 7 (2.2) 138 (44.1) 29 (9.3) 103 (33.1) 19 (6.1)
Fatigue 107 (34.2) 4 (1.3) 110 (35.1) 13 (4.2) 87 (28.0) 3 (1.0)
Pruritus 59 (18.8) 0 104 (33.2) 6 (1.9) 110 (35.4) 1 (0.3)
Rash 81 (25.9) 2 (0.6) 126 (40.3) 15 (4.8) 102 (32.8) 6 (1.9)
Nausea 41 (13.1) 0 81 (25.9) 7 (2.2) 50 (16.1) 2 (0.6)
Pyrexia 18 (5.8) 0 58 (18.5) 2 (0.6) 21 (6.8) 1 (0.3)
Decreased appetite 34 (10.9) 0 56 (17.9) 4 (1.3) 39 (12.5) 1 (0.3)
Increase in alanine amino‑ 
transferase level
12 (3.8) 4 (1.3) 55 (17.6) 26 (8.3) 12 (3.9) 5 (1.6)
Vomiting 20 (6.4) 1 (0.3) 48 (15.3) 8 (2.6) 23 (7.4) 1 (0.3)
Increase in aspartate amino‑ 
transferase level
12 (3.8) 3 (1.0) 48 (15.3) 19 (6.1) 11 (3.5) 2 (0.6)
Hypothyroidism 27 (8.6) 0 47 (15.0) 1 (0.3) 13 (4.2) 0
Colitis 4 (1.3) 2 (0.6) 37 (11.8) 24 (7.7) 36 (11.6) 27 (8.7)
Arthralgia 24 (7.7) 0 33 (10.5) 1 (0.3) 19 (6.1) 0
Headache 23 (7.3) 0 32 (10.2) 1 (0.3) 24 (7.7) 1 (0.3)
Dyspnea 14 (4.5) 1 (0.3) 32 (10.2) 2 (0.6) 13 (4.2) 0
Treatment‑related adverse event 
leading to discontinuation
24 (7.7) 16 (5.1) 114 (36.4) 92 (29.4) 46 (14.8) 41 (13.2)
*  The safety population included all the patients who received at least one dose of study drug. The severity of adverse events was graded ac‑
cording to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.
†  The treatment‑related adverse events listed here were those reported in at least 10% of the patients in any of the three study groups.
Table 3. Adverse Events.*
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combination of ipilimumab and nivolumab in 
the context of negative PD-L1 expression is of 
interest in melanoma as well as in other tumor 
types in which PD-1 checkpoint inhibitors are 
under evaluation.
The incidence of adverse events in this study 
was, in general, lowest in the nivolumab group 
and highest in the combination group. The over-
all incidence of treatment-related adverse events 
of grade 3 or 4 was higher in the combination 
group than in either monotherapy group, as a 
result of a higher incidence of most adverse 
events — in particular, hepatic toxic events, for 
which the rates of grade 3 or 4 elevations of the 
aminotransferase levels were 6.1% (for aspartate 
aminotransferase) and 8.3% (for alanine amino-
transferase) in the combination group and ap-
proximately 1 to 2% in each of the monotherapy 
groups. In general, the safety profile of the com-
bination therapy was consistent with previous ex-
perience with nivolumab or ipilimumab alone.5,9,10 
No new safety signals were identified, and there 
were no drug-related deaths in the combination 
group. Adverse events were manageable with 
established treatment guidelines, and most select 
adverse events resolved with the use of immune-
modulatory agents.
In conclusion, among patients with previously 
untreated advanced melanoma, we found longer 
progression-free survival and higher rates of ob-
jective response with nivolumab alone and with 
the combination of nivolumab and ipilimumab 
than with ipilimumab alone. The management 
of adverse events with the combination therapy 
suggests that it can be used safely in a broad 
range of clinical settings.
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